Timber Hill’s Vertex Pharmaceuticals VRTX Stock Holding History

Timber Hill’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-6,405	Closed	-$1.04M	–	273
2018 Q1	$1.04M	Buy	+6,405	New	+$1.05M	0.16%	123
2015 Q1	–	Sell	-8,396	Closed	-$1.01M	–	2645
2014 Q4	$997K	Buy	+8,396	New	+$946K	﹤0.01%	1442
2014 Q3	–	Sell	-18,875	Closed	-$1.8M	–	2857
2014 Q2	$1.79M	Buy	+18,875	New	+$1.32M	0.01%	1249
2014 Q1	–	Sell	-21,865	Closed	-$1.73M	–	3033
2013 Q4	$1.63M	Buy	21,865 +11,221	+105%	+$781K	0.01%	1514
2013 Q3	$807K	Buy	+10,644	New	+$847K	﹤0.01%	2109

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Timber Hill's VRTX Position: Q2 2018 in Review

Timber Hill sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 6,405 shares — an estimated $1.04M sold.

Timber Hill first reported a position in VRTX in Q3 2013 and held it in 5 quarters. The position peaked at $1.79M in Q2 2014. 690 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

Timber Hill reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Timber Hill sold 6,405 Vertex Pharmaceuticals shares in Q2 2018, an estimated $1.04M.
Timber Hill first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 5 quarters.
Timber Hill's Vertex Pharmaceuticals position peaked at $1.79M in Q2 2014.
690 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Timber Hill's 13F filing for Q2 2018, filed 9 Aug 2018.